Navigation Links
REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart
Date:8/7/2009

ISELIN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced today that REPEL-CV Bioresorbable Adhesion Barrier has received the endorsement of Kids With Heart National Association for Children's Heart Disorders, Inc. Michelle L. Rintamaki, Director of Kids With Heart, stated, "We want to inform parents of children with congenital heart defects about this new surgical device that reduces the risks associated with adhesions during repeat open-heart surgical procedures."

About Adhesions

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surrounding tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the patient risk, length and cost of the surgical procedure.

About REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions. It was recently approved by the US Food and Drug Administration for use in pediatric patients who undergo staged open-heart surgical procedures.

About Kids With Heart NACHD, Inc.

The organization was formed in 1985 with the main mission of providing support, information, and education to the families of children living with congenital heart defects and to promote public awareness of the issues that these families live with on a day to day basis. It is a 501(c)3 organization entirely supported by volunteers.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the commercialization of REPEL-CV(TM) Bioresorbable Adhesion Barrier and the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technologies.

Statements in this press release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Reference is made to the company's Annual Report on Form 10-KSB for the year ended December 31, 2008, for a description of these, as well as other, risks and uncertainties.

www.kidswithheart.org


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
2. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
3. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
4. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
5. Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study
6. Nanoengineered barrier invented to protect plastic electronics from water degradation
7. Barrier Therapeutics to Merge Into Stiefel Laboratories
8. Study Reveals Greatest Barrier to Green Supply Chain Initiatives
9. Physicists tweak quantum force, reducing barrier to tiny devices
10. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
11. Breaking barriers with nanoscale lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 2017 , ... Dr. Asher Kimchi, Founder and Chairman of the International ... at the 22nd World Congress on Heart Disease held in Vancouver, BC, Canada. In ... Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with Co-Chairmen Dr. John A. Elefteriades ...
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017 /PRNewswire/ ... , a personalized genetic evaluations company, today announced ... their partnership investigating a genetic mutation implicated in ... extend the partnership for a second case involving ... year, the KCNQ2 Cure Alliance and Pairnomix entered ...
(Date:7/18/2017)... ... , ... Sourcing custom glass or quartz parts can be a daunting task. ... execute your job can take many hours of emails, phone calls and on-line research. ... showcase the company’s capabilities and core custom categories, and enables you to start the ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope Foundation won the 2017 ... of the Allotrope Framework for commercial use. , The Bio-IT World Best Practices ... elevate the critical role of information technology in modern biomedical research, but also ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
Breaking Biology News(10 mins):